Monthly Formulary Amendments – December 2021

Monthly Formulary Amendments Documents list any NICE Technology Appraisals, NICE Guidelines, RMOC Guidance, MHRA Drug Safety Updates, and National Patient Safety Alerts published in the previous calendar month which may have an impact on local formularies and guidelines.  This document is for APCs, and formulary committees to ensure formularies remain up to date, and in line with latest NICE guidance and safety information.

It includes a suggested formulary position for APCs/Formulary Committees, together with a summary of any financial/commissioning implications. The purpose of the document is to support consistent decision making by APCs.

This information is produced for use by NHS healthcare professionals and RDTC stakeholders.

Monthly Horizon Scanning Report – December 2021

Monthly horizon scanning reports are designed to inform the NHS about new products, significant changes to product licenses, significant new guidance, and decisions that have been made by recognised bodies

This information is produced for use by NHS healthcare professionals. 

Growth Contrast Tool

Overview

The growth contrast tool is intended to help CCGs identify important local effects on prescribing costs. The figures are derived by comparing growth in prescribing costs and items in selected CCGs with what might have happened if national growth patterns had applied. Comparing actual growth with counterfactuals based on national growth patterns should remove the effect of system-wide changes (e.g. price increases, patent expiries, discontinuations, shortages, implementation of national guidance, etc.) & bring local effects into focus.

Data Period

April 2021 to December 2021

Frequency

Quarterly

Respiratory System

Overview

This report looks at prescribing trends in primary care for the Respiratory System at CCG and STP level with particular focus on bronchodilators and corticosteroids. Prescribing data is weighted with QoF registers, and also uses HES data to measure prescribing to outcomes. The report also calculates the potential opportunity cost for respiratory drugs based on the NHS England Right Care indicators.

If you have any queries about the content of the report please contact us at nuth.nyrdtc.rxsupp@nhs.net

Frequency

Quarterly

Data Period

January 2019 to December 2021

Monthly Horizon Scanning Report – Dec 2020

Monthly horizon scanning reports are designed to inform the NHS about new products, significant changes to product licenses, significant new guidance, and decisions that have been made by recognised bodies. 

This information is produced for use by NHS healthcare professionals. 

Long-Term Use Of PPIs – Bulletin

Long-term use of PPIs is not recommended in several indications as it has been linked to adverse effects including hypomagnesaemia, vitamin B12 deficiency, increased fracture risk and increased risk of MI.

This bulletin aims to highlight the current national guidance, potential adverse effects associated with long term PPI use and prescribing patterns on a CCG Level.

This review is older than 18 months; in view of the continued emergence of new evidence, readers are recommended to re-check the biomedical literature.

There are three versions of this publication; please select the appropriate version for your region below.